Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Mantle-Cell 9Recurrence 5Lymphoma 4Lymphoma, B-Cell 3Dendritic Cell Sarcoma, Interdigitating 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cytokine Release Syndrome 1Aggression 1

Interventions

Cyclophosphamide 155Rituximab 148Etoposide 84fludarabine phosphate 73Peripheral Blood Stem Cell Transplantation 68Mycophenolic Acid 63Busulfan 62Filgrastim 59Melphalan 58Tacrolimus 54Whole-Body Irradiation 51Cytarabine 46fludarabine 45Radiotherapy 43Methotrexate 41Granulocyte Colony-Stimulating Factor 41Cyclosporine 41Vincristine 35Antilymphocyte Serum 35Carmustine 33Doxorubicin 29Prednisone 26Thiotepa 25Bendamustine Hydrochloride 24Methylprednisolone 22Ifosfamide 22Dexamethasone 22thymoglobulin 21sargramostim 20plerixafor 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Non-Hodgkin × glofitamab × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06534437 2025-09-29

JASPIS-01

Ryvu Therapeutics SA

Phase 2 Recruiting
178 enrolled
Lymphoid

Aggression, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡